Clinical Trial Detail

NCT ID NCT03248570
Title Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

prostate adenocarcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.